Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30171 _______ ...

Nav 1.7 Prion Undisclosed C9orf72 Huntington NEUROPATHIC PAIN PRION DISEASE NEUROLOGY ALS HUNTINGTON'S • Selectively repress expression of a mutant allele while allowing for the expression of the healthy allele 13 • Blocking Nav1.7 in the DRG is expected to prevent the transmission of nociceptive pain signals to the brain • Progressive, with no disease modifying therapy Fabry Disease (isaralgagene civaparvovec or ST-920) | --- | --- | --- | --- | |-------|-------|-------|------------------------------------ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30171 ______ ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2023 Earnings Conference Call April 27, 2023 8:30 AM ET Company Participants Louise Wilkie - VP, IR and Corporate Communications Alexander D. Macrae - President and CEO D. Mark McClung - EVP and COO Prathyusha Duraibabu - SVP, Principal Accounting Officer and CFO Jason D. Fontenot - SVP and Chief Scientific Officer Nathalie Dubois-Stringfellow - SVP and Chief Development Officer Bettina M. Cockroft - CMO Conference Call Participants Benjamin Burnett - Stifel Grego ...

Forward-Looking Statements Pioneering and Delivering the Future of Genomic Medicines This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to our focus on key strategic priorities, the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential t ...

Pioneering and Delivering the Future of Genomic Medicines Forward-Looking Statements 2 Four Clinical-Stage Programs Advancing Towards Potential Commercialization In-House Manufacturing Provides Flexibility and Control Sangamo in 2023: Value Thesis 1 2 Pioneer in CAR-Tregs • TX200 renal transplant Ph1/2 study progresses, with possible acceleration to prove biology and platform value. Second wave of potentially transformative autoimmune and neurology programs advancing into the clinic • Second of four wholly- ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2022 Results Conference Call February 22, 2023 4:30 PM ET Company Participants Louise Wilkie - VP of IR and Corporate Communications Sandy Macrae - Chief Executive Officer Mark McClung - Chief Operating Officer Prathyusha Duraibabu - Chief Financial Officer Jason Fontenot - Chief Scientific Officer Nathalie Dubois-Stringfellow - Chief Development Officer Bettina Cockroft - Chief Medical Officer Andy Ramelmeier - Head of Technical Operations Conference Call Partici ...

Company Overview - The company is a clinical-stage biotechnology firm with no approved products or product revenues, relying on successful clinical trial results for future success [16]. - The company has incurred significant operating losses since inception and anticipates continued losses for the foreseeable future, indicating a need for substantial additional funding [16]. - The company relies heavily on collaborations with larger biopharmaceutical companies for revenue generation and product development, which poses risks if conflicts arise [16]. - The company faces significant competition in biotechnology and genomic medicine, which may impact its market position [16]. - The company has limited experience in manufacturing and relies heavily on third-party manufacturers, which could lead to unexpected costs and supply interruptions [16]. Financial Performance - Total revenues for 2022 were $111,299,000, a slight increase from $110,701,000 in 2021 [556]. - Research and development expenses rose to $249,898,000 in 2022, compared to $230,819,000 in 2021, reflecting a 8.9% increase [556]. - The net loss for 2022 was $192,278,000, compared to a net loss of $178,297,000 in 2021, indicating a 7.8% increase in losses [556]. - Total current assets decreased to $300,327,000 in 2022 from $398,769,000 in 2021, a decline of 24.6% [554]. - Total liabilities decreased to $267,551,000 in 2022 from $346,580,000 in 2021, a reduction of 22.8% [554]. - Deferred revenues decreased significantly from $85,711,000 in 2021 to $51,780,000 in 2022, a decline of 39.6% [554]. - The company reported a basic and diluted net loss per share of $1.25 for 2022, compared to $1.23 in 2021 [556]. - Cash and cash equivalents decreased to $100,444,000 in 2022 from $178,872,000 in 2021, a drop of 43.8% [554]. - The total stockholders' equity decreased to $294,958,000 in 2022 from $375,343,000 in 2021, a decline of 21.4% [554]. - The net loss for the year ended December 31, 2022, was $192.3 million, compared to a net loss of $178.3 million in 2021 and $121.1 million in 2020 [565]. - Cash, cash equivalents, and restricted cash at the end of 2022 totaled $101.9 million, down from $180.4 million at the end of 2021 [565]. - The company had capital resources of $307.5 million as of December 31, 2022, consisting of cash, cash equivalents, and marketable securities [569]. - The company reported stock-based compensation expenses of $31.7 million in 2022, slightly down from $33.0 million in 2021 [565]. - The company experienced a net cash used in operating activities of $223.6 million in 2022, compared to $233.3 million in 2021 [565]. Currency and Risk Exposure - The company reported foreign currency transaction losses of $3.1 million in 2022, highlighting exposure to foreign currency risk [539]. - A 10% strengthening or weakening in foreign currency rates would have increased or decreased net loss for the year ended December 31, 2022, by approximately $3.3 million [538]. - The company is exposed to credit risk due to investments in financial instruments, with established policies to manage this risk [597]. Collaboration and Revenue Sources - Revenue from major collaboration agreements for 2022 included 36% from Novartis, 35% from Kite Pharma, and 26% from Biogen [588]. - The Company recognized total revenue of $39.728 million related to the Novartis agreement in 2022, an increase from $37.944 million in 2021, reflecting a growth of approximately 4.7% [626]. - The upfront license fee received from Novartis was $75 million, with potential additional earnings of up to $420 million in development milestones and $300 million in commercial milestones [623]. - Under the collaboration with Biogen, the Company received an upfront license fee of $125 million and could earn up to approximately $2.4 billion in total milestone payments [629]. - The Company had deferred revenue of $9.6 million related to the Novartis agreement as of December 31, 2022, down from $40.9 million in 2021, indicating a decrease of approximately 76.5% [626]. - The Company had deferred revenue of $132.2 million related to the Biogen agreement as of December 31, 2022 [637]. - Kite Pharma agreement includes an upfront payment of $150.0 million and potential milestone payments totaling up to $3.0 billion [643]. - Revenue recognized under the Kite agreement was $38.6 million in 2022, an increase from $25.5 million in 2021 [652]. Operational Challenges and Future Outlook - The company plans to continue funding operations through collaborations, strategic partnerships, and equity securities issuance [569]. - Management believes existing resources will be sufficient to fund operations for at least the next 12 months [569]. - The company raised substantial doubt about its ability to continue as a going concern due to ongoing development projects requiring significant expenditures [571]. - The Company plans to implement cost preservation measures, including deferring certain R&D programs and pausing new hiring, to address liquidity needs [573]. - Management believes that the planned actions will provide sufficient liquidity to meet financial obligations over the next twelve months [575]. - The Company is actively seeking additional capital through various financing options, including public or private equity, debt financings, and strategic collaborations [577]. Asset Management - The company’s investment portfolio consists of high-quality securities, with minimal interest rate risk, and is not leveraged [536]. - The fair value of cash equivalents and marketable securities is classified as Level 1 for money market funds and Level 2 for other securities, indicating a reliance on observable market prices [618]. - The Company has cash equivalents totaling $50,820,000 and marketable securities amounting to $207,033,000 as of December 31, 2022, leading to total cash equivalents and marketable securities of $257,853,000 [617]. - Total cash equivalents and marketable securities as of December 31, 2022, amounted to $258.743 million, a decrease from $406.057 million in 2021, representing a decline of approximately 36.3% [619]. Stock and Compensation - The Company has stock options and RSUs outstanding totaling 18,560,755 as of December 31, 2022, which are anti-dilutive and excluded from diluted net loss per share calculations [612]. - The Company awarded 4,349,795, 2,140,785, and 2,517,101 Restricted Stock Units (RSUs) during the years ended December 31, 2022, 2021, and 2020, respectively [724]. - Total stock-based compensation expense recognized was $31.7 million, $33.0 million, and $25.7 million for the years ended December 31, 2022, 2021, and 2020, respectively [726]. - Employee stock-based compensation expense was determined using the Black-Scholes option valuation model for stock options and employee share purchases under the ESPP [727]. Legal and Regulatory Matters - The company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the position will be sustained upon examination [605]. - The company evaluates its property and equipment for impairment whenever events indicate that the carrying amount may not be recoverable [599]. - The Company has not identified any impairment of goodwill or indefinite-lived intangible assets as of December 31, 2022 [590].

Pioneering the Future of Genomic Medicines November 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, CAR-Treg and other te ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Jason Fontenot - Chief Scientific Officer Prathyusha Duraibabu - Chief Financial Officer Bettina Cockroft - Chief Medical Officer Mark McClung - Chief Operating Officer Conference Call Participants Gena Wang - Barclays Yanan Zhu - Wells Fargo Ritu Baral - Co ...